P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

(2009) D. N. Juurlink et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology

(2009) W. Kuliczkowski et al.   EUROPEAN HEART JOURNAL

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

(2009) C. Varenhorst et al.   EUROPEAN HEART JOURNAL

Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome

(2008) Corinne Frere et al.   AMERICAN JOURNAL OF CARDIOLOGY

P2Y 12 Antagonism

(2008) Alan D. Michelson   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

(2008) KA Kim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations

(2008) SP Myrand et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

(2008) David S. Small et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2

(2008) E. T. Williams et al.   DRUG METABOLISM AND DISPOSITION

Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects

(2008) Kyoung-Ah Kim et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention

(2008) Boris Aleil et al.   JACC-Cardiovascular Interventions

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

(2008) David S. Small et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

(2008) C. Steven Ernest et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance

(2008) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

(2008) David Erlinge et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin

(2008) Martine Gilard et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The reversible P2Y12antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

(2008) N. L. DOVLATOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

(2008) K. UMEMURA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

(2008) Jean-Philippe Collet et al.   LANCET

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

(2008) Tabassome Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment

(2007) Dominick J. Angiolillo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19⁎2 allele on clopidogrel responsiveness

(2007) Pierre Fontana et al.   THROMBOSIS RESEARCH

Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

(2007) Steven R. Steinhubl et al.   THROMBOSIS RESEARCH